Publication in refereed journal
香港中文大学研究人员 ( 现职)
| 马碧如教授 (肿瘤学系) |
全文
| 数位物件识别号 (DOI) http://dx.doi.org/10.1016/j.cgh.2013.08.040 |
引用次数
Web of Sciencehttp://aims.cuhk.edu.hk/converis/portal/Publication/11WOS source URL
其它资讯
摘要Colorectal cancer (CRC) is the third most commonly diagnosed cancer worldwide. Several important scientific discoveries in the molecular biology of CRC have changed clinical practice in oncology. These included the comprehensive genome-wide profiling of CRC by the Cancer Genome Atlas Network, the discovery of mutations along the RAS-RAF signaling pathway as major determinants of response to antibodies against the epidermal growth factor receptor, the elucidation of new molecular subsets of CRC or gene signatures that may predict clinical outcome after adjuvant chemotherapy, and the innovative targeting of the family of vascular endothelial growth factor and receptors. These new data have allowed oncologists to individualize drug therapy on the basis of a patient's tumor's unique molecular profile, especially in the management of metastatic CRC. This review article will discuss the progress of personalized medicine in the contemporary management of CRC.
着者Wong A, Ma BBY
期刊名称Clinical Gastroenterology and Hepatology
出版年份2014
月份1
日期1
卷号12
期次1
出版社WB Saunders
页次139 - 144
国际标準期刊号1542-3565
电子国际标準期刊号1542-7714
语言英式英语
关键词Colorectal Cancer; Gene Signatures; KRAS Mutation
Web of Science 学科类别Gastroenterology & Hepatology; GASTROENTEROLOGY & HEPATOLOGY
